Cowen Reiterates Outperform Rating on Moderna (MRNA), Sees Latest Kids Data as Providing a Strategic Benefit
Tweet Send to a Friend
Cowen analyst Tyler Van Buren reiterated an Outperform rating on Moderna (NASDAQ: MRNA), following the company's data report from KidCOVE ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
